Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting the curative potential of adoptive T‐cell therapy for cancer

13 Dec 2013

Abstract excerpt

Adoptive T-cell therapy (ACT) is a potent and flexible cancer treatment modality that can induce complete, durable regression of certain human malignancies. Long-term follow-up of patients receiving tumor-infiltrating lymphocytes (TILs) for metastatic melanoma reveals a substantial subset that experienced complete, lasting tumor regression - and may be cured. Increasing evidence points to mutated gene products as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24329789
DOI: 10.1111/imr.12132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting the curative potential of adoptive T‐cell therapy for cancerPMID 24329789Read ↗

Adoptive T-Cell Therapy for Cancer.Semantic proximity Read ↗

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.Semantic proximity Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read ↗

Cancer immunotherapy for metastasis: past, present and futureSemantic proximity Read ↗

Long-term efficacy of adoptive cell therapy is determined by host CD8 <sup>+</sup> T cells and undermined by lymphodepleting preconditioningSemantic proximity Read ↗

Adoptive immunotherapy for cancer: the next generation of gene‐engineered immune cellsSemantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Adoptive Cell TherapySemantic proximity Read ↗

Adoptive cell transfer as personalized immunotherapy for human cancer.Semantic proximity Read ↗

Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression AntigensSemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.